The stock of Hikma Pharmaceuticals Plc (LON:HIK) hit a new 52-week low and has GBX 1538.52 target or 7.00% below today’s GBX 1654.32 share price. The 7 months bearish chart indicates high risk for the GBX 3.95B company. The 1-year low was reported on Nov, 4 by Barchart.com. If the GBX 1538.52 price target is reached, the company will be worth GBX 276.50 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock decreased 5.20% or GBX 90.68 on November 4, hitting GBX 1654.32. About 2.42 million shares traded hands or 312.19% up from the average. Hikma Pharmaceuticals Plc (LON:HIK) has declined 22.09% since April 8, 2016 and is downtrending. It has underperformed by 23.18% the S&P500.
Hikma Pharmaceuticals Plc (LON:HIK) Ratings Coverage
Out of 14 analysts covering Hikma Pharmaceuticals PLC (LON:HIK), 13 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 93% are positive. GBX 2990 is the highest target while GBX 1936 is the lowest. The GBX 2511.58 average target is 51.82% above today’s (GBX 1654.32) stock price. Hikma Pharmaceuticals PLC has been the topic of 88 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The stock has “Overweight” rating given by JP Morgan on Tuesday, August 18. The rating was maintained by Stifel Nicolaus with “Buy” on Friday, June 24. The stock of Hikma Pharmaceuticals Plc (LON:HIK) earned “Overweight” rating by JP Morgan on Friday, September 23. On Thursday, December 24 the stock rating was maintained by AlphaValue with “Buy”. The stock has “Overweight” rating given by Barclays Capital on Tuesday, August 18. The stock has “Buy” rating given by Jefferies on Monday, September 12. The rating was maintained by JP Morgan on Tuesday, August 23 with “Overweight”. AlphaValue maintained Hikma Pharmaceuticals Plc (LON:HIK) on Thursday, January 7 with “Add” rating. JP Morgan maintained Hikma Pharmaceuticals Plc (LON:HIK) on Thursday, August 25 with “Overweight” rating. The rating was maintained by JP Morgan with “Overweight” on Tuesday, January 19.
More news for Hikma Pharmaceuticals Plc (LON:HIK) were recently published by: Fool.Co.Uk, which released: “Is Hikma Pharmaceuticals plc the best FTSE 100 healthcare stock to own after …” on August 24, 2016. Fool.Co.Uk‘s article titled: “Hikma Pharmaceuticals plc set for FTSE 100 re-entry and Inmarsat plc for ejection” and published on May 27, 2016 is yet another important article.
Hikma Pharmaceuticals Plc is a pharmaceutical company. The company has a market cap of 3.95 billion GBP. The Firm develops, makes and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa region and Europe. It has a 24.27 P/E ratio. The Company’s divisions include Branded, Injectables, Generics and Others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.